Angiotensin II Type 2 Receptor Agonists (ATRAGs) –Unlocking the potential of a new class of drugs.

Read more

Financial reports

Read more

Upcoming events

2024-05-17 - 2024-05-22

ATS 2024

2024-09-07 - 2024-09-11


Read more

Who we are

Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life- changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology.

We have a strong history of collaboration with the scientific community, which has led to a wealth of preclinical data and ongoing clinical research in multiple indications to prove the AT2 receptor biology. Embedded in our approach is the determination to find holistic solutions for patients and their families.

Mechanism of Action

The novel and multimodal mechanism of action of C21 targets the underlying fibrosis in IPF by stimulating the protective arm of the renin-angiotensin system (RAS). Consequently, there is an upstream effect in terms of promoting alveolar repair and maintenance of
alveolar integrity thereby reducing fibrosis formation, stabilizing disease, and increasing lung capacity.

What we do

Vicore is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG).

Almee™ (an investigational medical device pending FDA clearance) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis.

Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF.

With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore. >> View Pipeline

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market.